Explore

Trendline Trendline
Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products

Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products

Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products
Trendline Trendline
Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth
Trendline Trendline
Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth
Reuters Reuters
Pfizer pins post 2028 return to growth on new obesity and cancer drugs

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine.
Trendline Trendline
Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments

Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments

Pfizer Reports Strong First-Quarter Results and Reaffirms 2026 Guidance Amid Strategic Developments
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
Pfizer's Strategic Moves Set Stage for Growth Beyond 2029 Amid Legal and Market Developments

Pfizer's Strategic Moves Set Stage for Growth Beyond 2029 Amid Legal and Market Developments

Pfizer's Strategic Moves Set Stage for Growth Beyond 2029 Amid Legal and Market Developments
Reuters Reuters
Novo Nordisk slightly raises outlook as first-quarter profit beats forecast

Novo Nordisk slightly raises outlook as first-quarter profit beats forecast

COPENHAGEN, May 6 (Reuters) - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook for the year was slightly improved.
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data